Merus’ (MRUS) “Buy” Rating Reiterated at Guggenheim

Guggenheim restated their buy rating on shares of Merus (NASDAQ:MRUS) in a research report released on Wednesday morning,Benzinga reports.

A number of other equities research analysts also recently issued reports on MRUS. HC Wainwright reiterated a “buy” rating and issued a $85.00 target price on shares of Merus in a research report on Monday, December 2nd. Citigroup increased their price objective on Merus from $89.00 to $97.00 and gave the stock a “buy” rating in a report on Monday, December 9th. The Goldman Sachs Group assumed coverage on Merus in a research note on Thursday, November 21st. They issued a “buy” rating and a $73.00 target price on the stock. UBS Group began coverage on Merus in a research note on Thursday, October 24th. They set a “buy” rating and a $72.00 price target for the company. Finally, Needham & Company LLC reissued a “buy” rating and issued a $85.00 price target on shares of Merus in a research note on Monday, December 9th. One analyst has rated the stock with a sell rating, fourteen have issued a buy rating and two have issued a strong buy rating to the company. According to data from MarketBeat, Merus currently has an average rating of “Buy” and a consensus price target of $85.92.

Merus Price Performance

Shares of MRUS opened at $40.20 on Wednesday. The company has a market capitalization of $2.75 billion, a price-to-earnings ratio of -10.18 and a beta of 1.11. The business’s 50-day moving average is $41.55 and its 200-day moving average is $47.22. Merus has a fifty-two week low of $37.77 and a fifty-two week high of $61.61.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of MRUS. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its stake in shares of Merus by 17.0% in the third quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 84,200 shares of the biotechnology company’s stock worth $4,207,000 after purchasing an additional 12,212 shares during the period. GSA Capital Partners LLP bought a new position in Merus in the 3rd quarter worth approximately $675,000. State of New Jersey Common Pension Fund D bought a new position in Merus in the 3rd quarter worth approximately $1,870,000. US Bancorp DE bought a new stake in shares of Merus in the third quarter valued at approximately $103,000. Finally, HighTower Advisors LLC bought a new stake in shares of Merus in the third quarter valued at approximately $358,000. Institutional investors and hedge funds own 96.14% of the company’s stock.

About Merus

Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer and castration-resistant prostate cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1.